Minocycline oral dosage forms for the treatment of acne

1. A minocycline oral dosage form for the treatment of acne, comprising:

(i) an intragranular blend of:

90 mg of minocycline hydrochloride;

108 mg of the matrix-forming polymer hydroxypropyl methylcellulose; and

152 mg of an intragranular lactose, wherein the matrix-forming polymer hydroxypropyl methylcellulose is a slow dissolving carrier; and

(ii) 41 mg of extragranular lactose monohydrate, wherein the extragranular lactose is a fast dissolving carrier, a portion of which completely or partially encapsulates or coats the intragranular blend;

(iii) 3.0 mg of silicon oxide; and

(iv) 6.0 mg of magnesium stearate,

wherein the dosage form has a total weight of 400 mg and provides a patient with about 1 mg/kg of the minocycline in a slow, continuous fashion, without an initial load dose, that effectively treats acne of the patient by the once daily administration of the dosage form.

2. A kit comprising:

the minocycline oral dosage form of claim 1 ; and

information that the oral dosage form may cause one or more adverse effects.

3. The kit of claim 2 , wherein the one or more adverse effects is selected from group consisting of one or more of: headache, fatigue, dizziness, pruritus, malaise, mood alteration, somnolence, urticaria, tinnitus, vertigo, dry mouth, and myalgia.

4. The kit of claim 3 , further comprising additional information about one or more deleterious effects selected from the group consisting of: gastrointestinal disorders, blurred vision, autoimmune syndromes, and adverse renal reactions.

5. The kit of claim 2 , further comprising instructions for administering the oral dosage form.

6. The minocycline oral dosage form of claim 1 , further comprising a film coat.